Impact News +++ ABIONYX Pharma Is Launching a Capital Increase With Cancellation of Preferential Subscription Rights in... (Business Wire) +++ ABIONYX Aktie -4,27%

DAXOR Aktie

>DAXOR Performance

1 Woche: -3,7%

1 Monat: -5,5%

3 Monate: +8,3%

6 Monate: +37,7%

1 Jahr: +37,7%

laufendes Jahr: +43,4%

>DAXOR Aktie

Name:

DAXOR CORP. DL -,01

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US2394671034 / 871275

Symbol/ Ticker:

DX5 (Frankfurt)

Kürzel:

FRA:DX5, ETR:DX5, DX5:GR

Index:

Webseite:

https://www.daxor.com/

Profil:

Daxor Corporation is a medical instrumentation and..
>Volltext..

Marktkapitalisierung:

52.12 Mio. EUR

Unternehmenswert:

52.34 Mio. EUR

Umsatz:

0.91 Mio. EUR

EBITDA:

1.57 Mio. EUR

Nettogewinn:

1.53 Mio. EUR

Gewinn je Aktie:

0.31 EUR

Schulden:

0.22 Mio. EUR

Liquide Mittel:

Operativer Cashflow:

-0.69 Mio. EUR

Bargeldquote:

Umsatzwachstum:

-97%

Gewinnwachstum:

6.55%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

DAXOR

Letzte Datenerhebung:

16.12.25

>DAXOR Kennzahlen

Aktien/ Unternehmen:

Aktien: 4.96 Mio. St.

Frei handelbar: 42.75%

Leerverk. Aktien: -

Rückkaufquote: -

Mitarbeiter: -

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Strong buy

Kursziel: 79.59%

Bewertung:

KGV: 33.59

KGV lG: -

KUV: 57.32

KBV: 1.71

PEG-Ratio: 9.85

EV/EBITDA: 33.25

Rentabilität:

Bruttomarge: 85.67%

Gewinnmarge: 168.48%

Operative Marge: 173.24%

Managementeffizenz:

Gesamtkaprendite: 5.12%

Eigenkaprendite: 5.26%

>DAXOR Peer Group

Es sind 599 Aktien bekannt.

>DAXOR Chart & Kurs - Frankfurt
- Boerse Frankfurt
- >Profi Charts

>DAXOR News

21.10.25 - 14:03	Daxor CEO Michael Feldschuh to Engage Investors at Exclusive Maxim Growth Summit (GlobeNewswire EN)
	Summit Features a Select Group of 40 Promising Healthcare Companies at Premier Small-Cap Investor Event...

30.09.25 - 14:03	Daxor Unveils New FDA-Cleared BVA Analyzer Amid Strong Market Demand and Pivotal Clinical Data at HFSA (GlobeNewswire EN)
	Three Studies Validate BVA-Guided Care Significantly Cuts Hospital Readmissions and Boosts Survival in High-Cost Heart Failure Segments...

23.09.25 - 14:03	Daxor Corporation Unveils Breakthrough Next-Gen BVA Analyzer at HFSA Annual Scientific Meeting (GlobeNewswire EN)
	Additional New Clinical Data To Be Presented Driving a New Standard of Care in Volume Measurement...

07.08.25 - 13:57	Daxor Corporation Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis System (GlobeNewswire EN)
	Management Expects High Demand Driven by Speed, Simplicity, and Clinical Precision...

21.07.25 - 15:42	Daxor declares $0.0432 dividend (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

07.05.25 - 14:03	Florida Healthcare Leader Embraces Daxor Blood Volume Analysis Technology (GlobeNewswire EN)
	Daxor's ezBVA Lab Service Marks New Standard in Precision Fluid Management...

22.04.25 - 14:03	Daxor Corporation to Exhibit at the 45th International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions (GlobeNewswire EN)
	Daxor Brings Advanced Blood Volume Analysis Solutions to Elite Heart and Lung Transplantation Forum...

17.04.25 - 14:03	Daxor Corporation to Showcase Innovative Blood Volume Analysis at MedAxiom Cardiovascular Transforum Spring 2025 (GlobeNewswire EN)
	WellStar Health System to Highlight New BVA-Driven Strategy That Significantly Reduces Kidney Injury Following LVAD Implantation...

10.04.25 - 14:03	Daxor Corporation Submits 510(k) to FDA for Next-Generation Blood Volume Analyzer (GlobeNewswire EN)
	Advanced BVA System Designed for Faster, Simpler Bedside Testing...

02.04.25 - 14:03	Daxor Corporation Announces New Data from Duke University and Highlights Key BVA Insights at American College of Cardiology′s 74th Annual Scientific Session and Expo (GlobeNewswire EN)
	BVA and Pressure Session Attracted 400+ Clinicians; Duke University Showcased Valuable New BVA Findings in Dedicated Poster Presentation...

28.03.25 - 13:03	Daxor Expands Blood Volume Analysis Technology Across Midwest, Wisconsin, and New Jersey Healthcare Networks (GlobeNewswire EN)
	Regional Medical Leaders Embrace Daxor's ezBVA Lab Service...

04.03.25 - 22:57	Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2024 (GlobeNewswire EN)
	Strong Start to 2025 with Unaudited Revenue Increases Leading to Cash Flow Positive Operating Company Results...

04.03.25 - 21:57	Daxor Corporation to Host Investor Conference Call to Discuss Fiscal Year 2024 Financial Results and Provide a Corporate Update on March 6, 2025 (GlobeNewswire EN)
	Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will host an investor conference call on Thursday, March 6, 2025, at 4:30 p.m. ET....

04.03.25 - 15:03	Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders (GlobeNewswire EN)
	Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology today issued a corporate update in a Letter to Shareholders filed in its certified shareholder report on Form N-CSR on March 04, 2025 from CEO & President, Michael Feldschuh....

04.03.25 - 14:09	Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders (GlobeNewswire EN)
	Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology today issued a corporate update in a Letter to Shareholders filed in its certified shareholder report on Form N-CSR on March 15, 2023 from CEO & President, Michael Feldschuh....

04.03.25 - 14:03	Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023 (GlobeNewswire EN)
	Strong Start to 2025 with Unaudited Revenue Increases Leading to Cash Flow Positive Operating Company Results...

28.02.25 - 14:03	Daxor Expands Blood Volume Analysis Services at Major Midwest Healthcare Center (GlobeNewswire EN)
	Premier 735-Bed Healthcare Facility Implements ezBVA Lab Service to Enhance Cardiovascular Outpatient Care...

19.02.25 - 14:03	Daxor Corporation Announces New Data on Blood Volume Analysis from Duke and Yale Universities Presented at THT 2025 (GlobeNewswire EN)
	Two Groundbreaking Studies on Fluid Management: Pulmonary Artery Pressure Monitoring Falls Short, New Diuretic Insights Emerge...

18.02.25 - 14:03	Daxor to Exhibit at World′s Largest Critical Care Conference (GlobeNewswire EN)
	Daxor's Blood Volume Analysis (BVA) Technology Takes Center Stage at SCCM 2025...

14.02.25 - 14:03	Daxor′s Blood Volume Analysis Uncovers Hidden Heart Failure Subtype in Nearly 1 in 5 Patients, Enabling Targeted Treatment (GlobeNewswire EN)
	Case Reports in the Journal of the American College of Cardiology Underscore the Critical Role of Blood Volume Analysis in Optimizing Heart Failure Treatment...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Der Mensch ward zum Tun und nicht zum Vernünfteln erschaffen. Aber eben deswegen, weil er nicht dazu erschaffen ward, hängt er diesem mehr als jenem nach. - Gotthold Ephraim Lessing

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram